CN
111.png
banner
Your present location:Home/About us/News/Company/Scientists discover a new method of liquid biopsy for liver cancer

Scientists discover a new method of liquid biopsy for liver cancer

Release date:2023-01-03

Simultaneous analysis of mutations and methylations

in circulating cell-free DNA for hepatocellular carcinoma detection


SCIENCE TRANSLATIONAL MEDICINE 23 Nov 2022 Vol 14, Issue 672

DOI: 10.1126/scitranslmed.abp8704

Abstract

Cell-free DNA (cfDNA)–based liquid biopsy is a promising approach for the early detection of cancer. A major hurdle is the limited yield of cfDNA from one blood draw, limiting the use of most samples to one test of either mutation or methylation. Here, we develop a technology, Mutation Capsule Plus (MCP), which enables multiplex profiling of one cfDNA sample, including simultaneous detection of genetic and epigenetic alterations and genome-wide discovery of methylation markers. With this technology, we performed de novo screening of methylation markers on cfDNA samples from 30 hepatocellular carcinoma (HCC) cases and 30 non-HCC controls. The methylation markers enriched in HCC cfDNA were further profiled in parallel with a panel of mutations on a training cohort of 60 HCC and 60 non-HCC cases, resulting in an HCC detection model. We validated the model in an independent retrospective cohort with 58 HCC and 198 non-HCC cases and got 90% sensitivity with 94% specificity. Furthermore, we applied the model to a prospective cohort of 311 asymptomatic hepatitis B virus carriers with normal liver ultrasonography and serum AFP concentration. The model detected four of the five HCC cases in the cohort, showing 80% sensitivity and 94% specificity. These findings demonstrate that the MCP technology has potential for the discovery and validation of multiomics biomarkers for the noninvasive detection of cancer. This study also provides a comprehensive database of genetic and epigenetic alterations in the cfDNA of a large cohort of HCC cases and high-risk non-HCC individuals.

For details, please visit https://www.science.org/doi/10.1126/scitranslmed.abp8704


Why choose Magen?

----Over 10 years R&D and production experience of nucleic acid extraction !

----Abundant production line with over 500 extraction kits, satisfy customized demand

----High and Stable quality, supplied over 100,000,000 preps viral extraction kits for COVID-19 all over the world

Back to list
Leave A Message

Leave A Message

    Please provide us with the information below, and we'll contact you as soon as possible.

This site uses cookies to improve your online experience,allow you to share content on social media,measure traffic to this website and display customised ads based on your browsing activity.